Accounting for an Isobaric Interference Allows Correct Determination of Folate Vitamers in Serum by Isotope Dilution-Liquid Chromatography-Tandem MS\(^1\)\(^2\)

Zia Fazili and Christine M. Pfeiffer*

National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA

Abstract
Mild and prolonged oxidative degradation of 5-methyltetrahydrofolate (5-methylTHF) leads to the biologically inactive pyrazino-s-triazine derivative of 4\(\alpha\)-hydroxy-5-methylTHF (MeFox). MeFox and the biologically active 5-formyltetrahydrofolate (5-formylTHF) are isobaric compounds that behave similarly during chromatographic and mass separation, making coelution and misidentification likely. Our published routine liquid chromatography-tandem MS (LC-MS/MS) method did not discern between 5-formylTHF and MeFox, measuring the sum of these compounds at a mass to charge ratio (m/z) of 474-327 as 5-formylTHF. We modified this method to separate MeFox and 5-formylTHF by either chromatography or unique mass transitions and then applied the 2 methods to serum specimens to determine typical concentrations of these compounds. The 2 unique transitions (m/z: 5-formylTHF, 474–299; MeFox, 474–284) showed good sensitivity [limit of detection (nmol/L): 5-formylTHF, 0.21; MeFox, 0.34], selectivity (no interfering peaks), spiking recovery (mean ± SD: 5-formylTHF, 103 ± 3.4%; MeFox, 94 ± 10%), and low imprecision (CV: 5-formylTHF, 3.9% at 2.4 nmol/L; MeFox, 5.1% at 2.9 nmol/L). The mass separation method detected 5-formylTHF in the same specimens as the chromatographic separation method. Analysis of several thousand serum specimens showed that the majority (~85%) contained MeFox at <3 nmol/L but no detectable 5-formylTHF concentrations, some (~14%) contained 5-formylTHF at <0.5 nmol/L, and a few specimens contained 5-formylTHF at >1 nmol/L and MeFox at >10 nmol/L. In summary, serum can contain 5-formylTHF high enough to contribute to total folate and contains MeFox that will bias total folate if not appropriately separated. Including measurements of MeFox and 5-formylTHF along with the other folate vitamers will enhance assessments of the association between biologically active folate and health effects. J. Nutr. 143: 108–113, 2013.

Introduction
Folate vitamers are important cofactors in 1-carbon metabolism, participating in methylation reactions and DNA synthesis; suboptimal folate status may modulate chronic diseases such as cardiovascular disease, cancer, and/or cognitive impairment (1). There is great interest in exploring associations between folate vitamers and health effects, and recent advances in the application of tandem MS to the measurement of folate vitamers make such studies possible (2). However, the analysis of folates in serum is complex because of numerous folate derivatives that exist in different oxidation states and 1-carbon substitutions.

Folates are also sensitive to oxidative degradation (3,4). Serum 5-methyltetrahydrofolate (5-methylTHF)\(^3\), the main circulating folate form, can readily undergo mild reversible oxidation to 5-methyldehydrofolate (3,5) (Supplemental Fig. 1). Severe or prolonged oxidation can convert 5-methylTHF or 5-methyldehydrofolate to 4\(\alpha\)-hydroxy-5-methylTHF, an intermediate product also called hmTHF (3–7). In the absence of a reducing agent, hmTHF undergoes structural rearrangement to form a pyrazino-s-triazine derivative (4–8). This stable oxidation product of 5-methylTHF is also known as MeFox, the methyl folinate oxidation product. MeFox is not biologically active (3,5) and was previously reported in long-term frozen, stored serum and plasma specimens and even in fresh-frozen specimens (9–11; the authors, however, referred to this com-

\(^1\)Author disclosures: Z. Fazili and C. M. Pfeiffer, no conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the official views or positions of the CDC/Agency for Toxic Substances and Disease Registry.

\(^2\)Supplemental Text 1 and Supplemental Figures 1–3 are available from the “Online Supporting Material” link in the online posting of the article and from the same link in the online table of contents at http://jn.nutrition.org.

\(^*\)To whom correspondence should be addressed. E-mail: CPfeiffer@cdc.gov.

\(^3\)Abbreviations used: FA, folic acid; 5-formylTHF, 5-formyltetrahydrofolate; hmTHF, 4\(\alpha\)-hydroxy-5-methyltetrahydrofolate; LC-MS/MS, liquid chromatography-tandem MS; LOD, limit of detection; MeFox, pyrazino-s-triazine derivative of 4\(\alpha\)-hydroxy-5-methyltetrahydrofolate; 5-methylTHF, 5-methyltetrahydrofolate; m/z, mass to charge ratio; QC, quality control; SPE, solid phase extraction.
pound as hmTHF, even though they stated that it was the pyrazino-s-triazine derivative of hmTHF). It is not known whether MeFox is formed only in vitro or may already be present in vivo.

MeFox and 5-formyltetrahydrofolate (5-formylTHF) are isobaric compounds and as such form the same mass to charge (m/z) parent to product ion pairs during ionization, making coelution and misidentification during liquid chromatography-tandem MS (LC-MS/MS) analysis likely. Our published isotope-dilution LC-MS/MS method (12,13) did not discern between 5-formylTHF and MeFox and we reported the measured concentrations as 5-formylTHF. Only one LC-MS/MS method analyzing serum folate vitamers has been reported so far that chromatographically separates these 2 compounds (11). Using this method, the authors did not find any 5-formylTHF in 168 fresh-frozen serum specimens. Other methods did not incorporate the analysis of MeFox into their profile of analytes (14–16) and either reported no (14,15) or low (16) concentrations of 5-formylTHF in a rather limited number of serum specimens (n ≤ 32).

Our first objective was to improve our published LC-MS/MS method such that it accurately captured all folate vitamers that can be present in serum, as well as MeFox, the oxidation product of 5-methylTHF. To achieve that, we modified our method to allow separation and accurate quantitation of MeFox and 5-formylTHF while maintaining the desirable features of the method, such as short runtime, isocratic separation, good sensitivity, and precision. Our second objective was to apply the improved LC-MS/MS method to a large number of serum specimens to determine what the typical concentrations of MeFox in serum are and whether 5-formylTHF is present in addition to MeFox. This information will help investigators decide which folate forms to measure in studies that assess the relationship of folate and health effects.

Materials and Methods

Reagents, materials, and serum specimens. Folate monoglutamate standards ([6S]-5-methylTHF, [6S]-5-formylTHF, folic acid [FA], [6S]-tetrahydrofolate, [6R]-5,10-methylenetetrahydrofolate, and [6S]-MeFox), together with their respective 13C5-labeled analogs, were purchased from Merck Cie. Other reagents and solvents were of ACS reagent grade unless stated otherwise. Purified water (18 MΩ·cm) from an Aqua Solutions water purification system was used for all reagents and solutions. All sample handling was performed under gold-fluorescent light. All folate calibrators were prepared as described earlier (12,13). For a detailed description of the preparation of MeFox calibrators, see Supplemental Text 1. In-house prepared, serum quality control (QC) pools (low, [6S]-medium, and high levels) and several thousand serum specimens from a CDC study and U.S. blood bank were stored at −70°C. The serum specimens from the large CDC study contained 0.5% (wt/v) L-ascorbic acid added at the time of specimen preparation. Study participants provided informed consent. The study protocol was approved by the CDC Research Ethics Review Board.

Sample processing. A 6-point calibration curve (0–100 nmol/L for 5-methylTHF with 10 nmol/L 13C5-5-methylTHF; 0–50 nmol/L for other folates, including MeFox with 2.5 nmol/L each of 13C5-labeled folate), serum QC samples (duplicate analysis of 3 levels/analysis), and unknown serum specimens were carried through all sample processing steps, which were conducted according to an automated, reversed-phase, solid phase extraction (SPE) procedure as previously reported (12,13).

Analysis of native serum specimens by LC-MS/MS. Extracted serum samples were analyzed by one or both modified LC-MS/MS methods that allowed quantitation of MeFox and 5-formylTHF either by chromatographic separation (method 2) or by mass separation (method 3) (Table 1). Specifics regarding the instrumentation and instrument parameters used can be found in Supplemental Text 1. As part of the method validation process, we applied both methods to 3 serum QC pools that were spiked with 5-formylTHF (0.5, 2.0, and 3.5 nmol/L) at the time of pool preparation. We applied method 2 to a set of serum specimens (n = 132) to assess whether native samples contain one or both compounds. Samples found to contain 5-formylTHF were then analyzed by method 3 for confirmation. Finally, we applied method 3 to several thousand serum specimens from a CDC study and U.S. blood bank to assess typical concentrations of MeFox and 5-formylTHF in a large sample set. We assessed the correlation between MeFox and 5-methylTHF in this large sample set using Pearson correlation.

Method validation experiments. To assess whether the complete analytical sample preparation process, including SPE, leads to the formation of MeFox, we used method 2 (no 13C5-MeFox added) to measure peak areas in the multiple reaction monitoring (MRM) transition of 13C5-MeFox (m/z 479 → 327) for 50 serum specimens. We compared the areas with those found in the 13C5-MeFox transitions of a 13C5-5-methylTHF calibrator that did not undergo sample processing. Increased areas in processed serum samples would indicate potential 5-methylTHF oxidation (of the internal standard) during sample preparation and analysis.

We assessed whether 5-methylTHF stock solutions prepared approximately annually and stored at ~70°C for a period of up to 9 y (eight 100-mg/L solutions containing 1% ascorbic acid) showed any loss of 5-methylTHF or increase in MeFox with increasing age. We performed subsequent injections of freshly prepared, 500-nmol/L working solutions (69% water:1% acetic acid:30% methanol) containing 0.5% ascobic acid of each yearly stock by method 2 (n = 3 injections/preparation) and monitored the MRM transitions for 5-methylTHF and MeFox to assess whether areas changed from one preparation to another and for other folate forms to ensure that there were no interfering peaks appearing with the older preparations.

We assessed method performance characteristics such as selectivity, sensitivity, accuracy, imprecision, and ion suppression behavior for

### Table 1. LC-MS/MS method conditions for a published procedure (method 1) and for newly adapted chromatographic (method 2) and mass (method 3) separation methods

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Method 1</th>
<th>Method 2</th>
<th>Method 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample extraction and clean-up</td>
<td>Automated, reversed-phase SPE using 96-well phenyl plates (Bond Elute, Varian) on an 8-probe Gilson 215 processor</td>
<td>One part sample extract + one part mobile phase</td>
<td>None</td>
</tr>
<tr>
<td>Dilution of sample extract after SPE</td>
<td>None</td>
<td>69% water:1% acetic acid: 30% methanol</td>
<td>49.5% water:0.5% acetic acid:40% methanol:10% acetonitrile</td>
</tr>
<tr>
<td>Isocratic mobile phase</td>
<td>49.5% water:0.5% acetic acid:40% methanol:10% acetonitrile</td>
<td>49.5% water:0.5% acetic acid:40% methanol:10% acetonitrile</td>
<td></td>
</tr>
<tr>
<td>MS transitions [m/z]</td>
<td>MeFox + 5-formylTHF 474–327</td>
<td>MeFox + 5-formylTHF 474–327</td>
<td>MeFox + 5-formylTHF 474–299</td>
</tr>
<tr>
<td>Chromatographic resolution</td>
<td>Coelution of MeFox and 5-formylTHF</td>
<td>Baseline separation of MeFox and 5-formylTHF</td>
<td>Coelution of MeFox and 5-formylTHF</td>
</tr>
</tbody>
</table>

1. 5-formylTHF, 5-formyltetrahydrofolate; LC-MS/MS, liquid chromatography-tandem MS; MeFox, pyrazino-s-triazine derivative of 4a-hydroxy-5-methyltetrahydrofolate; m/z, mass to charge ratio; SPE, solid phase extraction.
method 3. To confirm the selectivity of the new mass transitions in method 3, we prepared individual calibrator solutions for each folate form in sample solvent (49% water:1% acetic acid:40% methanol:10% acetonitrile) containing 0.5% ascorbic acid at concentrations representing or exceeding the upper limit of the calibration range (50, 100, and 200 nmol/L) and analyzed each preparation in triplicate.

To determine method sensitivity, we calculated the limit of detection (LOD) for each analyte. We serially diluted the “low” QC pool with 0.1% ascorbic acid and estimated the SD at a concentration of zero (σ0) by extrapolating repeat analyze measurements (n = 9) made near the detection limit in these dilutions. The LOD was defined as 3σ0.

We assessed the accuracy of method 3 by spike recovery. We added a calibrator mixture of 5-formylTHF and MeFox at 3 concentrations (2.0, 5.0, and 10 nmol/L) in triplicate to a serum specimen that was also measured in triplicate for endogenous concentrations of these 2 compounds. The spike recovery was calculated as the measured concentration difference between the spiked and unspiked sample divided by the nominal concentration of the spike.

Method 3 imprecision (within-run, between-run, and total CV) was assessed by analyzing serum QC pools in duplicate (at the beginning and end of each run bracketing patient samples) for an extended period of time (122 analyses for a period of 1 y).

We also assessed the ion suppression behavior of method 3 by using a postcolumn infusion procedure. We infused analyte and internal standard (1.6 μmol/L at a constant flow of 10 μL/min) to elevate the baseline of each mass transition to ~1 × 106 ion counts/s. We then injected various serum samples as test specimens and evaluated the degree of ion suppression as the relative deviation of the baseline observed in the elution time window for each analyte and internal standard.

Results

Adaptation of LC-MS/MS method to separate MeFox and 5-formylTHF. Our published LC-MS/MS method 1 achieved rapid isocratic separation of several folate vitamers: 5-methylTHF, 5-formylTHF, tetrahydrofolate, 5,10-methenyl-tetrahydrofolate, and FA. However, MeFox and 5-formylTHF coelute at 3.1 min and both compounds had predominant transitions at the same m/z of 474 → 327. In method 2, we adapted the chromatography of method 1 to separate MeFox and 5-formylTHF by use of a more polar isocratic mobile phase and by diluting one part of the SPE-extracted sample with one part of the mobile phase to more closely match the sample composition to the mobile phase composition (Table 1). Method 2 allowed nearly baseline separation of MeFox (3.62 min) and 5-formylTHF (4.17 min) at m/z 474 → 327 (Supplemental Fig. 2) while retaining the separation of the other folate vitamers.

In method 3, we adapted the mass detection of method 1 to separate MeFox and 5-formylTHF by use of selective transitions. Although both compounds had the same protonated molecular ion [M + H]+ of 474.4 and the same predominant fragment ion of 327.2, they also produced less abundant (two-thirds less) unique fragment ions: 284.2 for MeFox and 299.2 for 5-formylTHF. By optimizing the MS parameters for these selective transitions (Supplemental Text 1), we were able to accurately separate and quantitate these 2 compounds without changing the sample preparation or isocratic chromatography of method 1.

Method validation. Using method 2, we assessed whether sample preparation or storage leads to formation of MeFox. We prepared serum samples without the addition of 13C5-MeFox, carried them through the complete procedure, and monitored the transition for 13C5-MeFox (m/z 474 → 327) to assess how much of the 13C5-5-methylTHF was “oxidized.” We found on average 0.3% of the 13C5-5-methylTHF area in the 13C5-MeFox transition of processed serum samples. This amount was about the same as in 13C5-5-methylTHF internal standard solutions that did not undergo sample processing (0.4%). The amount of MeFox was also very similar to what we found in 5-methylTHF stock solutions (100 mg/L) stored for up to 9 y at −70°C in the presence of 1% ascorbic acid (0.2%). We therefore concluded that our sample processing did not generate additional MeFox beyond what was present at the beginning of processing and that high-concentration stock solutions are stable for many years if properly stored.

We analyzed 3 serum QC pools that were spiked with 5-formylTHF (0.5, 2.0, and 3.5 nmol/L) at the time of pool preparation with methods 2 and 3 to confirm that both methods separate MeFox and 5-formylTHF and achieve comparable quantitation of these 2 compounds. We found low MeFox concentrations (mean ± SD, nmol/L, n = 4 analyses; 1.13 ± 0.19, 1.04 ± 0.21, and 2.70 ± 0.43 by method 2 and 0.93 ± 0.05, 1.20 ± 0.04, and 2.74 ± 0.07 by method 3) in addition to 5-formylTHF concentrations (0.41 ± 0.25, 1.69 ± 0.42, and 2.84 ± 0.62 by method 2 and 0.56 ± 0.08, 2.13 ± 0.09, and 3.67 ± 0.15 by method 3). Although both methods produced comparable MeFox concentrations, the 5-formylTHF concentrations measured by method 3 corresponded better with the spiking levels than those measured by method 2. Furthermore, the SDs for both compounds in these 4 analyses were much lower for method 3 compared with method 2. Method 2 had an additional disadvantage: the use of a more polar mobile phase resulted in peak broadening, which together with the need to dilute the extracted sample led to a loss in sensitivity. Because method 3 had better features for routine use, we proceeded to validate it for implementation as our new routine method.

When we examined the new transitions in method 3 for spurious signal contributions from other folate forms, we found good selectivity with virtually no contributing signals (<0.01%). We also confirmed that high concentrations of MeFox (or 13C5-MeFox) did not contribute any signal to transitions used for other folate forms (including the new 5-formylTHF transition). Considering that the new transitions in method 3 represent less abundant fragment ions, they had good sensitivity, with LODs of 0.34 and 0.21 nmol/L for MeFox and 5-formylTHF, respectively. Using a postcolumn infusion procedure, we established that matrix effects and ion suppression were not present.

Due to the lack of reference materials for 5-formylTHF and MeFox, we determined the accuracy of method 3 by an isotope spike recovery. We found complete recovery (mean ± SD) for 5-formylTHF (103 ± 3.4%) and MeFox (94 ± 10%) added to serum (Table 2) and a nearly perfect linear relationship between the 3 spiking levels and the measured concentrations in the spiked sample (Supplemental Fig. 3), additionally confirming the respective selectivity of the new transitions. We obtained low imprecision after routinely using method 3 for 1 y (122 runs): 4.4, 3.9, and 5.0% for 5-formylTHF (2.38 nmol/L) and 3.6, 5.1, and 5.7% for MeFox (2.93 nmol/L) for within-run, between-run, and total CV, respectively. No imprecision exceeded 10% for the low-concentration QC pool (0.67 and 1.54 nmol/L for 5-formylTHF and MeFox, respectively).

Analysis of native serum specimens. We applied method 2 to a set of serum specimens (n = 132) to assess whether native samples contain one or both compounds in question. The analysis showed exclusively MeFox with the exception of 2 specimens that had low 5-formylTHF concentrations (0.52 and 0.56 nmol/L). We confirmed the presence of 5-formylTHF in these 2 specimens by method 3 (1.28 and 0.47 nmol/L).
We then applied method 3 to a large set of several thousand serum specimens to assess the typical concentrations of MeFox and 5-formylTHF. We found detectable 5-formylTHF concentrations in ~15% of samples [90th percentile (95% CI), nmol/L: 0.24 (0.239–0.248)]; a few samples had 5-formylTHF concentrations >1 nmol/L. Most samples (99%) had detectable MeFox concentrations [median (95% CI), nmol/L: 1.35 (1.32–1.39)] and <1% of samples had MeFox concentrations >10 nmol/L. We found a weak ($r = 0.19$) but significant correlation ($P < 0.001$) between MeFox and 5-methylTHF, with MeFox concentrations increasing with increasing 5-methylTHF concentrations. We observed 3 different patterns of these 2 compounds found in native serum specimens (Fig. 1): the low MeFox/low 5-formylTHF pattern was encountered most frequently, whereas the low MeFox/high 5-formylTHF and high MeFox/low 5-formylTHF patterns were encountered much less frequently. The figure also shows that the unselective mass transition of 474→327 captured the sum of the selective MeFox (474→284) and 5-formylTHF (474→299) transitions quite well.

**Discussion**

This manuscript presents an improved and validated, routine, isotope-dilution LC-MS/MS procedure for the measurement of key folate forms in serum. The method allows separation and accurate quantitation of the 2 isobaric compounds MeFox, a stable oxidation product of 5-methylTHF, and 5-formylTHF, a minor folate vitamin, in addition to other folate vitamins. The method has been applied to several thousand serum specimens for a period of 1 year, providing to our knowledge the first data from an extensive sample set that shows what the typical concentrations of MeFox and 5-formylTHF in serum are.

Only a small number of research groups have so far developed isotope-dilution LC-MS/MS methods for the analysis of folate vitamins in serum. Several investigators limited their methods to the analysis of 5-methylTHF and sometimes FA (17–21), partly because their research interests were in the area of folate bioavailability and kinetics. Although some investigators expanded their methods to analyze a wider spectrum of folate vitamins, including 5-formylTHF (12–16,22), none of these methods incorporated the analysis of MeFox as part of the folate profile. Hannisdal et al. (11) reported the first and so far only LC-MS/MS method that measures the main folate vitamins in serum in addition to MeFox.

The present study confirms the finding by Hannisdal et al. (11) that the isobaric compounds MeFox and 5-formylTHF have to be separated for correct quantitation of folate forms in serum. Whereas the authors opted for chromatographic separation using gradient elution and an unselective mass transition of 474→327 for detection, we explored 2 different approaches to separate MeFox and 5-formylTHF: chromatographic separation using an adapted isocratic elution (method 2) and mass separation using unique mass transitions (method 3). Both approaches allowed us to separate the 2 isobaric compounds; however, the chromatographic separation approach had several shortcomings such as impaired sensitivity due to peak broadening and poor imprecision. The newest generation tandem mass spectrometer offered an improvement in sensitivity and allowed us to further explore the second approach using unique mass transitions while retaining the time-tested isocratic chromatography procedure from our published method 1. The new unique transitions for MeFox and 5-formylTHF in method 3 proved to be highly selective as well as sensitive. Compared with the LOD values reported by Hannisdal et al. (11) (MeFox 0.20 nmol/L, 5-formylTHF 0.52 nmol/L), the method 3 LOD values (MeFox 0.34 nmol/L, 5-formylTHF 0.21 nmol/L) were slightly higher for MeFox but lower for 5-formylTHF. The other performance

<table>
<thead>
<tr>
<th>Spiking level</th>
<th>Recovery</th>
<th>Concentration</th>
<th>MeFox</th>
<th>5-FormylTHF</th>
<th>MeFox + 5-FormylTHF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum blank</td>
<td></td>
<td>3.58 ± 0.06</td>
<td>&lt;1.00</td>
<td>4.30 ± 0.07</td>
<td></td>
</tr>
<tr>
<td>Serum + spike 1</td>
<td></td>
<td>7.22 ± 0.18</td>
<td>2.01 ± 0.07</td>
<td>5.95 ± 0.13</td>
<td></td>
</tr>
<tr>
<td>Serum + spike 2</td>
<td></td>
<td>13.1 ± 0.42</td>
<td>5.28 ± 0.16</td>
<td>9.09 ± 0.06</td>
<td></td>
</tr>
<tr>
<td>Serum + spike 3</td>
<td></td>
<td>22.3 ± 0.44</td>
<td>10.4 ± 0.25</td>
<td>14.6 ± 0.27</td>
<td></td>
</tr>
</tbody>
</table>

1 Values are mean ± SD. 5-formylTHF, 5-formyltetrahydrofolate; LOD, limit of detection; MeFox, pyrazino-s-triazine derivative of 4a-hydroxy-5-methyltetrahydrofolate; SPE, solid phase extraction.
2 Serum specimen was spiked with 3 levels (2, 5, and 10 nmol/L) of 5-formylTHF and MeFox and samples were processed by SPE for LC-MS/MS analysis by method 3 ($n = 3$ replicates/spike level).
3 Measured at $m/z$ transition of 474→284.
4 Measured at $m/z$ transition of 474→299.
5 Measured at $m/z$ transition of 474→284.
6 LOD for 5-formylTHF was 0.21 nmol/L.
parameters for method 3 were also very good; we found complete spiking recoveries (MeFox 94%, 5-formylTHF 103%) and low between-run imprecision after using the assay for an entire year (MeFox, 5.1% at 2.93 nmol/L, 5-formylTHF, 3.9% at 2.38 nmol/L). Hannisdal et al. (11) reported slightly lower spiking recoveries (MeFox, 82–94%; 5-formylTHF, 91–98%) and higher between-run imprecision (MeFox, 7.1% at 4.0 nmol/L; 5-formylTHF, 9.9% at 3.7 nmol/L).

The question has been raised whether MeFox is formed only in vitro or may already be present in vivo. Hannisdal et al. (11) observed that this compound was already present in fresh-frozen serum samples that were kept in an ice bath for maximum 150 min while the whole blood was allowed to clot. Our experiments have added new information. We have shown that our sample processing does not generate additional MeFox beyond what is present at the beginning of processing. Although this may not seem too surprising, because ascorbic acid is incorporated into all reagents used as part of sample processing to avoid folate oxidation, it is reassuring that there is no artifactual increase in MeFox as a result of sample manipulations at the bench. Furthermore, it was also reassuring to note that high-concentration stock solutions of 5-methylTHF can be stored for nearly a decade without any observed loss of 5-methylTHF or increase in MeFox. However, the question whether MeFox may already be present in vivo has yet to be answered.

We analyzed 2 sets of native serum samples: a smaller set (n = 132) by method 2 and a large set of several thousand samples by method 3. In the smaller set, we found 2 specimens with low 5-formylTHF concentrations that we confirmed with method 3. Hannisdal et al. (11) analyzed a similar size sample set (n = 168) and did not find any 5-formylTHF, possibly because their LOD was slightly higher than ours or because folate concentrations in the nonfortified Norwegian population were lower than in the fortified U.S. population. In the large sample set, we found detectable 5-formylTHF concentrations in ~15% of samples and a few samples had concentrations >1 nmol/L. This shows that 5-formylTHF needs to be included as a potential folate vitamer when developing an LC-MS/MS method. Overall, its contribution to total folate may be small, but in selected samples, it can contribute an amount that cannot be neglected. In the large sample set, we found detectable MeFox concentrations in almost all samples (99%) and very few samples (<1%) with concentrations >10 nmol/L. Our median concentration for MeFox of 1.35 nmol/L was comparable with the median of 2.3 nmol/L reported by Hannisdal et al. (11). Although MeFox concentrations are generally low, they will bias the total folate if MeFox is not appropriately separated from 5-formylTHF.

The present study provides some much-needed information on typical concentrations of MeFox and 5-formylTHF found in native serum specimens to help investigators decide which folate forms to measure in studies that investigate the relationship of folate and health effects. While it confirms previous observations that the isobaric compounds MeFox and 5-formylTHF have to be separated for correct quantitation of folate forms in serum, it provides evidence that 5-formylTHF cannot be ignored in the measurement process. This is to our knowledge the first study that has analyzed a large number of specimens with a sufficiently sensitive method to show the presence of 5-formylTHF, sometimes at notable concentrations. Although certified reference materials are not yet available for either MeFox or 5-formylTHF to verify absolute method accuracy, the validation experiments we performed indicate that the selective mass separation method presented here exhibits good accuracy. This new routine method also shows excellent performance characteristics, such as low, long-term imprecision. These features, in combination with the sample processing and chromatography procedure of the previously published method that has proven to be robust and rugged during almost 10 y of use in our laboratory, provide an invaluable improvement in the analysis of serum folate vitamers by LC-MS/MS.

Acknowledgments

The authors thank Neelima Paladugula for technical assistance and Dr. Ekaterina Paliakov for valuable suggestions regarding the separation of MeFox and 5-formylTHF. The authors also thank Drs. Per Ueland and Rita Hannisdal, University of Bergen, for providing a small amount of in-house synthesized MeFox for our initial analyses. Z.E designed the overall research project, conducted most of the research, analyzed the majority of the data, and wrote the initial draft, which was modified after feedback from C.M.P.; and C.M.P. designed the overall research project, analyzed the majority of the data, and has primary responsibility for content. Both authors read and approved the final manuscript.

Literature Cited


